VANCOUVER, B.C., CANADA (March 3rd, 2017) - M Pharmaceutical Inc. (CSE: MQ, OTCQB: MPHMF, FWB: T3F2), (the "Company" or “M Pharma”) announces that Kim Whittemore has been appointed to the Company’s Board of Directors.
“Kim Whittemore provides M Pharma with extensive knowledge and expertise within the women’s health space, a central focus of our business growth strategy,” said Gary Thompson, M Pharma’s President and CEO.
Kim Whittemore is a passionate advocate for women’s health and sexual health. She has vast experience in the fields of digital health, wearable tech and women’s health and through her management consulting practice, works with clients on business strategy and digital marketing. (Partial client list at kimwhit.com). Ms. Whittemore is a University of Pennsylvania International Relations graduate, completed MIT executive courses in Computer Science and has an advanced certificate in digital marketing. In her early career, Ms. Whittemore held senior executive positions with DecisionOne Corporation, Verizon and AT & T after beginning her career at the National Security Agency (NSA).
“As a C-Suite management consultant, Kim has developed and implemented go-to-market strategies in the healthcare space, and specifically within the women’s health space, including the launch of a digital health service for infertility treatments. Her experience and negotiating skills, noting that she has secured an eight figure licensing agreement with market leading companies, will be of great benefit to M Pharma,” said Mr. Thompson. “Kim’s experience and passion provide a great asset to our company and we are excited to have her join our team.”
“As new members continue to join our Board, I would like to thank Mr. George Tsafalas for his tremendous leadership and guidance in serving M Pharma since its inception. George is resigning from the Board to make way for Kim, but will continue to support the Company as a senior business consultant,” said Gary Thompson.
Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to C-103, a reformulation of orlistat, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights. The Company acquired an FDA cleared fertility product branded as ToConceive that represents its first offering in the women's health field and has recently acquired a suite of products, the foundation of which is based on a patented and FDA cleared topical gel combining menthol & L-arginine. This innovative formulation can be paired with many different ingredients to address a multitude of medical issues, including a female dysfunction application that been submitted for patent protection.
M Pharma trades on the Canadian Securities Exchange (CSE) under the ticker symbol “MQ” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F2.”
Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval, commercialization of the rights to the Company’s biomedical & drug technologies, and acquisition of new products. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company’s filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.
Notice regarding investigational devices: C-103 and Trimeo are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.